Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
20 févr. 2018 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 16h30 HE
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Wednesday, January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time ANN ARBOR, Mich., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
14 déc. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 déc. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
13 nov. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
09 nov. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, November 14, 2017 at 8:45 a.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
07 nov. 2017 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Host Analyst and Investor Day Event on October 17
10 oct. 2017 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
02 oct. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019...
Esperion Prices Public Offering of Common Stock
09 août 2017 21h20 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...